Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.

Much like Swizz Beatz himself, an artist known for blending diverse genres, the DB Kind of Two GMT reflects a unique ...

Rooted in the legacy of Sri Vasavi Thangamaaligai, a jewellery house serving customers since 1942 in Dindigul, Tamil Nadu, ...

The slew of litigation filed by states’ attorneys in the USA challenging Trump’s executive orders on citizenship, federal ...

Chandigarh: PGI's medical innovation, conceived and developed entirely in India, is set to redefine neuropathic pain ...

Explore the ONEXSUGAR, a cutting-edge handheld gaming device with dual screens, Android versatility, and powerful Snapdragon ...

Bengal’s Most Stylish, Kolkata prepares for an evening where fashion becomes the beholder and personalities shine brighter ...

Empuraan sets new records with massive advance bookings, aiming to redefine Malayalam cinema’s box office benchmarks.

A class action lawsuit was filed against Novo Nordisk A/S (NVO) by Levi & Korsinsky on January 24, 2025. The plaintiffs ...

Leading UAE companies are investing in AI-powered loyalty programmes, with a focus on creating seamless, high-value ...

Nikola Jokic's current NBA season has brought forth a debate that echoes through basketball history: can modern statistics redefine greatness? With Jokic's performance outpacing Michael Jordan's ...